“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Ultimovacs
Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.
Ultimovacs — 4 videos in collection
Ultimovacs is a biotechnology company developing novel immunotherapies against cancer. The lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT). Around 85% of all cancer types express high levels of hTERT. Therefore, UV1 has broad potential in a variety of different settings and combinations with other cancer treatments.
In this video, chief executive officer Carlos de Sousa reviews the company’s broad R&D pipeline and explains multiple upcoming catalysts.
Get access to the very latest content matched to your personal investment style.
